L 687901Alternative Names: Tetrahydroechinocandin B
Latest Information Update: 19 Nov 2001
At a glance
- Originator Merck & Co
- Class Antifungals
- Mechanism of Action Glucan synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Candidiasis
Most Recent Events
- 19 Nov 2001 No-Development-Reported for Candidiasis in USA (Unknown route)
- 07 Nov 1994 No-Development-Reported for Mycoses in USA (Unknown route)